Search Results 991-1000 of 16357 for monoclonal antibody

  1. Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants with Relapsed or Refractory Multiple Myeloma - Mayo Clinic

    Monoclonal plasma cells in the bone marrow ≥ 10% at ... Subject has known allergies, hypersensitivity, or intolerance to VELCADE, monoclonal antibodies ...

  2. Trial to Assess Safety and Effectiveness of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) - Mayo Clinic

    ... antibody MOR202 in adult subjects with in Anti-PLA2R Antibody Positive Membranous Nephropathy (newly diagnosed/relapsed/refractory). Participation ...

  3. Stem Cell Therapy Clinical Trials - Mayo Clinic Research

    Monoclonal antibodies, such as pembrolizumab, may block tumor growth in different ways by targeting certain cells. Giving dendritic cell therapy after ...

  4. Polymer Shielding of Vectors and Vaccines - Virology, Vector and Vaccine Engineering: Michael A. Barry - Mayo Clinic Research

    PEGylation also reduces the production of new antibody and cellular immune responses against Ad. The Virology, Vector and Vaccine Engineering Lab has ...

  5. Liver Cancer Clinical Trials - Mayo Clinic Research

    Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of ...

  6. CAR-T Cell Therapy Program - Clinical trials

    ... antibody (ANCA) associated vasculitis using primary samples and/or patient derived xenograft models. CD19-Directed CAR-T Cell Therapy for the Treatment of ...

  7. PTT-936, an Alpha Kinase 1 (ALPK1) Activator, Alone or in Combination with Anti-PD-1/L1 in Patients with Locally Advanced or Metastatic Solid Tumors - Mayo Clinic

    Treatment with commercially available or investigational large molecule cancer therapies, including monoclonal antibodies (mAbs), bispecific antibodies, ...

  8. A Study of Atezolizumab Alone or Combined with Immunomodulatory Drug and/or Daratumumab in Multiple Myeloma Patients - Mayo Clinic

    Receipt of ≥ 2 prior lines of therapy and progressed on treatment with an anti-CD38 monoclonal antibody (Cohort D3). Receipt of ≥ 4 lines of prior therapy ...

  9. Mayo Clinic Minute: Advances in multiple myeloma treatment

    We call it an immunoglobulin, or in our world, we call it a monoclonal protein. And so that can cause damage over time," says Dr. Cook. The damage caused by ...

  10. A Study Evaluating the Safety and Effectiveness of JCAR017 to Treat Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL) - Mayo Clinic

    Anti-CD20 monoclonal antibodies within 7 days prior to leukapheresis 11. Venetoclax within 4 days prior to leukapheresis 12. Idelalisib or duvelisib within ...